GlassScriptPhysician profile
Elvis Akpene Tanson
NPI 1720136138
$36,695.97
in general payments reported to CMS, 2019-2025
80 companies · $6,448 in 2025
The $6,448 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,532 · 2020: $4,026 · 2021: $5,279 · 2022: $5,315 · 2023: $5,377 · 2024: $4,718 · 2025: $6,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,429.78 |
| Education | $112.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,551.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,822.82 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $2,283.86 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $2,272.21 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Lilly USA, LLC | $1,931.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,759.18 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $1,233.47 | 2019-2025 | |
| Amgen INC. | $1,185.59 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,145.58 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $1,010.83 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $968.83 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $928.21 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Scilex Pharmaceuticals INC. | $885.33 | 2021-2025 | Ztlido |
| Allergan, INC. | $807.29 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $738.64 | 2019-2023 |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elvis Tanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.